Cecelia Fisher, MD
Internal Medicine · Nashville, TNNPI 1376585174
Payments from drug & device makers
Across 253 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$623
- Amgen$610
- Lilly USA, LLC$435
- Novo Nordisk$429
- AstraZeneca$418
- Esperion Therapeutics, Inc.$271
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,639100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 32 | $623 |
| Amgen | 32 | $610 |
| Lilly USA, LLC | 24 | $435 |
| Novo Nordisk | 26 | $429 |
| AstraZeneca(2 entities) | 28 | $418 |
| Esperion Therapeutics, Inc. | 8 | $271 |
| AbbVie | 12 | $235 |
| Exact Sciences | 11 | $183 |
| Amarin Pharma, Inc. | 11 | $166 |
| Johnson & Johnson | 8 | $150 |
| Boehringer Ingelheim | 6 | $119 |
| Abbott | 5 | $117 |
| Sanofi-aventis U.S. LLC | 6 | $96 |
| GSK | 5 | $91 |
| Novartis | 5 | $90 |
| Dexcom, Inc. | 3 | $58 |
| Insulet Corporation | 3 | $54 |
| Inspire Medical Systems, Inc. | 2 | $52 |
| Lundbeck LLC | 2 | $52 |
| Merck | 3 | $42 |
| Bayer | 2 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Radius Health, Inc. | 2 | $29 |
| Eisai Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Optinose US, Inc. | 1 | $23 |
| Ossur Americas, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,639 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 155 | $141,477 |
| OzempicSemaglutide | 80 | $70,575 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $49,529 |
| XareltoRivaroxaban | 34 | $46,052 |
| MounjaroTirzepatide | 37 | $39,061 |
| JanuviaSitagliptin Phosphate | 19 | $27,580 |
| TrulicityDulaglutide | 13 | $25,362 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $24,066 |
| JardianceEmpagliflozin | 21 | $24,012 |
| FarxigaDapagliflozin Propanediol | 24 | $22,201 |
| Victoza 3-PakLiraglutide | 16 | $15,007 |
| EntrestoSacubitril/Valsartan | 11 | $14,076 |
| LinzessLinaclotide | 16 | $13,275 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,413 |
| PremarinEstrogens, Conjugated | 33 | $10,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $623 | $152,270188 claims |
| Novo NordiskOzempic | $429 | $70,57580 claims |
| Lilly USA, LLCMounjaro, Trulicity | $435 | $64,42350 claims |
| MerckJanuvia, Janumet | $42 | $51,64637 claims |
| Johnson & JohnsonXarelto | $150 | $46,05234 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $119 | $29,12532 claims |
| AstraZenecaFarxiga | $418 | $22,20124 claims |
| AbbVieLinzess, Synthroid | $235 | $19,262114 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $91 | $17,86229 claims |
| NovartisEntresto | $90 | $14,07611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Nashville
- John AndersonNashville$1.5M
- Nancy DavisNashville$985K
- Wayne RileyNashville$536K
- Paul FerrellNashville$413K
- Cyndya Shibao MiyasatoNashville$364K
- Hilary TindleNashville$337K
- Harvey BowlesNashville$203K
- Jay MontgomeryNashville$174K
- Temidayo AbeNashville$113K
- Nader BahriNashville$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.